The obstacles and countermeasures of developing function of China＇s Unemployment insurance funds

The function of the unemployment insurance funds arc： ensuring the basic life and stabling employment, preventing unemployment and promoting employment, on the one hand, it guarantee basic livings of the unemploycd, in order to reduce the impact on the individual and society. On the other hand, it also has a function of stabling employment, preventing unemployment and promoting unemployed again obtain employment. In recent years, however, the unemployment insurance fund revenue has been greater than its expenditure, balance funds become more and more, it not only faces a risk of depreciation, also will cause the waste of funds. Therefore, improve the utilization rate of the uncmployment insurance fund itself and expand the function of the unemployment insurance fund, realize the sustainable development of unemployment insurance funds is great significance.

Nusinersen for spinal muscular atrophy types Ⅱ and Ⅲ:a retrospective single-center study in South Korea

Background This study investigated the efficacy and safety of nusinersen,an antisense oligonucleotide,in patients with spinal muscular atrophy(SMA)types II(OMIM:253,550)or III(OMIM:253,400),including those with severe scoliosis or requiring respiratory support via mechanical ventilation.Methods Data from 40 patients with genetically confirmed SMA who were treated with nusinersen at our institute from March 2019 to April 2022 were retrospectively analyzed.Of these,30 patients with an age of onset<3 years and not on permanent ventilation were selected.Clinical and genetic characteristics were investigated,and motor function was evaluated based on the Hammersmith Functional Motor Scale-Expanded(HFMSE)score.Results The mean age of symptom onset was 1.2 years.Most patients were diagnosed with SMA type II(27/30,90%).Nusinersen was administered via computed tomography-guided or direct intrathecal injection in 87%(26/30)and 13%(4/30)of the patients,respectively.At the 6-,14-,22-,and 26-month follow-ups,72%,71%,88%,and 86%of patients showed motor improvement,respectively,with mean changes in HFMSE scores of 2.10,2.88,4.21,and 5.29,respectively.Multivariable analysis showed that the use of noninvasive ventilation was associated with poorer outcomes of motor function.Conclusions Patients with SMA type II or III who received nusinersen treatment showed significant improvement in motor function.A longer treatment duration led to a higher number of patients with improved motor function.No significant side effects of nusinersen were observed.Patients with SMA,even those with severe scoliosis or on respiratory support,can be safely treated using nusinersen.